Author

Luc Biedermann

BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 96-WEEKS OPEN-LABEL EXTENSION PHASE FOLLOWINGTHE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL
BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 96-WEEKS OPEN-LABEL EXTENSION PHASE FOLLOWINGTHE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Luc Biedermann  et al.

BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 96-WEEKS OPEN-LABEL EXTENSION PHASE FOLLOWINGTHE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL
BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 96-WEEKS OPEN-LABEL EXTENSION PHASE FOLLOWINGTHE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

USING MACHINE LEARNING METHODS, CAN ANTIBIOTICS PREDICT A FUTURE RELAPSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE? – A POPULATION-BASED NESTED CASE-CONTROL STUDY USING MACHINE LEARNING METHODS
USING MACHINE LEARNING METHODS, CAN ANTIBIOTICS PREDICT A FUTURE RELAPSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE? – A POPULATION-BASED NESTED CASE-CONTROL STUDY USING MACHINE LEARNING METHODS

Luc Biedermann  et al.

THE USE OF ANTIBIOTICS INCREASES THE RISK OF RELAPSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE – A POPULATION-BASED NESTED CASE-CONTROL STUDY USING THE DANISH NATIONAL PATIENT REGISTRY
THE USE OF ANTIBIOTICS INCREASES THE RISK OF RELAPSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE – A POPULATION-BASED NESTED CASE-CONTROL STUDY USING THE DANISH NATIONAL PATIENT REGISTRY

Luc Biedermann  et al.

PROGNOSTIC VALUE OF INTESTINAL ULTRASOUND PARAMETERS FOR LONG-TERM OUTCOMES IN IBD PATIENTS – ONE YEAR INTERIM RESULTS OF THE TRUST BEYOND STUDY
PROGNOSTIC VALUE OF INTESTINAL ULTRASOUND PARAMETERS FOR LONG-TERM OUTCOMES IN IBD PATIENTS – ONE YEAR INTERIM RESULTS OF THE TRUST BEYOND STUDY

Luc Biedermann  et al.

IMPROVEMENT OF INTESTINAL ULTRASOUND PARAMETERS WITHIN 12 WEEKS AFTER TREATMENT INDUCTION IN CD AND UC PATIENTS - FIRST INTERIM ANALYSIS OF THE TRUST BEYOND STUDY
IMPROVEMENT OF INTESTINAL ULTRASOUND PARAMETERS WITHIN 12 WEEKS AFTER TREATMENT INDUCTION IN CD AND UC PATIENTS - FIRST INTERIM ANALYSIS OF THE TRUST BEYOND STUDY

Luc Biedermann  et al.

ONE-YEAR INTESTINAL ULTRASOUND IMPROVEMENTS IN UC PATIENTS ON BIOLOGIC OR JAKI THERAPY – INTERIM RESULTS OF THE TRUST BEYOND STUDY
ONE-YEAR INTESTINAL ULTRASOUND IMPROVEMENTS IN UC PATIENTS ON BIOLOGIC OR JAKI THERAPY – INTERIM RESULTS OF THE TRUST BEYOND STUDY

Luc Biedermann  et al.

A SURVEY BASED ASSESSMENT OF MANAGEMENT OF ESOPHAGEAL FOOD IMPACTIONS IN THE US AND EUROPE
A SURVEY BASED ASSESSMENT OF MANAGEMENT OF ESOPHAGEAL FOOD IMPACTIONS IN THE US AND EUROPE

Luc Biedermann  et al.

A PROSPECTIVE INTERVENTIONAL STUDY TO EVALUATE THE EFFECT OF HYPOXIA ON HEALTHY VOLUNTEERS AND PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ALTITUDE IBD STUDY
A PROSPECTIVE INTERVENTIONAL STUDY TO EVALUATE THE EFFECT OF HYPOXIA ON HEALTHY VOLUNTEERS AND PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ALTITUDE IBD STUDY

Luc Biedermann  et al.

BUDESONIDE ORODISPERSIBLE TABLETS ARE HIGHLY EFFECTIVE FOR RE-INDUCTION OF CLINICAL REMISSION IN RELAPSING ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE EOS-2 TRIAL
BUDESONIDE ORODISPERSIBLE TABLETS ARE HIGHLY EFFECTIVE FOR RE-INDUCTION OF CLINICAL REMISSION IN RELAPSING ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE EOS-2 TRIAL

Luc Biedermann  et al.

BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE FIRST 48-WEEKS OPEN-LABEL EXTENSION PHASE OF THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL
BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE FIRST 48-WEEKS OPEN-LABEL EXTENSION PHASE OF THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Luc Biedermann  et al.

SEX IMPACTS ENDOSCOPIC AND HISTOLOGICAL DISEASE ACTIVITY BUT NOT SYMPTOMS OR QUALITY OF LIFE IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS OF A NATIONWIDE PROSPECTIVE COHORT STUDY
SEX IMPACTS ENDOSCOPIC AND HISTOLOGICAL DISEASE ACTIVITY BUT NOT SYMPTOMS OR QUALITY OF LIFE IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS OF A NATIONWIDE PROSPECTIVE COHORT STUDY

Luc Biedermann  et al.

ODYNOPHAGIA AND RETROSTERNAL PAIN IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS – RATHER INDICATIVE OF DISEASE ACTIVITY THAN SIDE EFFECT OF THERAPY
ODYNOPHAGIA AND RETROSTERNAL PAIN IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS – RATHER INDICATIVE OF DISEASE ACTIVITY THAN SIDE EFFECT OF THERAPY

Luc Biedermann  et al.

RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 INSPIRE STUDY
RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 INSPIRE STUDY

Luc Biedermann  et al.

Item 1 - 14 / 14
1